The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
Hodanren Renews Call for Transparent Pricing for Kymriah
The Japanese Medical and Dental Practitioners for the Improvement of Medical Care (Hodanren) reiterated its push for more transparency in the pricing of Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) in a statement issued on May 22 in conjunction with…
To read the full story
Related Article
ORGANIZATION
- Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
December 26, 2025
- EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…